Literature DB >> 8337241

Movement dysfunction following central nervous system lesions: a problem of neurologic or muscular impairment?

J R Carey1, T P Burghardt.   

Abstract

In most of the scientific literature that discusses the common problem of resistance to passive movement in patients with central nervous system lesions, this clinical problem is ascribed to a mechanism involving uninhibited neural activity. This article reviews the literature related to an alternative explanation of stiffness in such patients, an explanation involving the mechanical orientation of myosin crossbridges. The conventional view of the crossbridge is that it is detached from actin filaments during the relaxed state of muscle. Information is presented, however, from animal studies indicating that a certain proportion of crossbridges bind weakly to actin even in the relaxed state. The muscles of patients with hypertonicity may undergo an adaptation that involves formation of a higher proportion of binding crossbridges. This results in abnormal stiffness in the muscle and impairs movement. Such crossbridge stiffness may be particularly elevated immediately after a previous contraction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8337241     DOI: 10.1093/ptj/73.8.538

Source DB:  PubMed          Journal:  Phys Ther        ISSN: 0031-9023


  3 in total

1.  Contribution of thixotropy, spasticity, and contracture to ankle stiffness after stroke.

Authors:  W Vattanasilp; L Ada; J Crosbie
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-07       Impact factor: 10.154

2.  Linear spring-damper model of the hypertonic elbow: reliability and validity.

Authors:  Patrick H McCrea; Janice J Eng; Antony J Hodgson
Journal:  J Neurosci Methods       Date:  2003-09-30       Impact factor: 2.390

3.  Effects of radial extracorporeal shock wave therapy on hand spasticity in poststroke patient.

Authors:  C Gjerakaroska Savevska; E Nikolikj Dimitrova; M Gocevska
Journal:  Hippokratia       Date:  2016 Oct-Dec       Impact factor: 0.471

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.